Ivermectin is currently used for about 27% of the world’s population. There are now 88 studies on IVM yielding 63% [52-71%] and 83% [74-89%] improvement for early treatment and prevention.
While the majority of higher-income countries with high vaccination rates are suffering recurring increases in covid-19 infections and hospitalisations, lower-income countries with low vaccination rates, who implement routine mass-prophylactic and early treatment drug administration (including ivermectin), have significantly lower infection rates.
